Pacific Biosciences of California, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$784M
↓-37.8% -$476Mvs FY2024
Total Liabilities
$779M
↑+3.3% +$25Mvs FY2024
Equity
$5M
↓-98.9% -$501Mvs FY2024
Cash
$64M
↑+15.1% +$8Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $784M | $1.26B |
| Current Assets | $375M | $496M |
| Cash | $64M | $55M |
| ST Investments | $216M | $335M |
| Receivables | $35M | $28M |
| Inventory | $49M | $59M |
| Other Current | $11M | $19M |
| Non-Current Assets | $409M | $765M |
| PPE | $24M | $31M |
| Goodwill | $318M | $318M |
| Intangibles | $15M | $390M |
| Investments | $0 | $0 |
| Other Non-Current | $52M | $27M |
| Total Liab+Eq | $784M | $1.26B |
| Current Liab. | $73M | $66M |
| Accounts Payable | $21M | $17M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $16M | $14M |
| Other CL | $36M | $36M |
| Non-Current Liab. | $706M | $688M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $706M | $688M |
| Equity | $5M | $507M |
| Retained Earnings | $2.70B | $2.15B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · PACB · Comparing FY2025 vs FY2024